A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise
This study has been completed.
First Posted: March 30, 2010
Last Update Posted: February 6, 2017
AstraZeneca, Bristol-Myers Squibb
Information provided by (Responsible Party):